Comparative Cohort Study of Long-term Safety Outcomes of Risankizumab Compared to Biologic Treatments for Ulcerative Colitis and Crohn’s Disease in a Real-world Setting in Sweden and Denmark

ENCePP Code of conduct

Yes

Data sources

• Data source(s):
  Sweden National Prescribed Drugs Register / Läkemedelsregistret

  Sweden National Cancer Register / Cancerregistret

  Danish registries (access/analysis)
• Data source(s), other:
  SWIBREG, Swedish National Patient Register, Swedish National Cause of Death Register, SMINET;
• Data sources (types):
  Administrative healthcare records (e.g., claims)

  Disease registry

  Pharmacy dispensing records

  Population registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Not applicable